AcquisitionsSep 16, 2026, 04:13 PM
CareDx Files Financials for Naveris Acquisition
AI Summary
CareDx, Inc. has filed an amendment to its Form 8-K to include the financial statements of Naveris, Inc., following its acquisition which closed on July 1, 2026. The filing provides the audited financial statements for Naveris for the year ended December 31, 2025, and unaudited statements for the three months ended March 31, 2026. Additionally, pro forma condensed combined financial information illustrating the effects of the acquisition is included. Naveris' key product, NavDx, is a blood-based test for viral-mediated cancers.
Key Highlights
- CareDx, Inc. filed an amendment to its 8-K to include financial statements for its acquisition of Naveris, Inc.
- The acquisition of Naveris, Inc. was completed on July 1, 2026.
- Naveris' lead product, NavDx, is a blood-based test for viral-mediated cancers.
- Audited financial statements for Naveris for the year ended December 31, 2025, are now filed.
- Unaudited financial statements for Naveris for the three months ended March 31, 2026, are now filed.
- Pro forma condensed combined financial information for the acquisition is included.
Price Impact
More from CDNA